Table 3

Multivariate analysis of TRM and relapse

VariableNRRLower CLUpper CLP
TRM, main effect*      
        Full intensity 1428 1.00    
        RIC 93 0.98 0.66 1.46 .92 
TRM, other significant factors      
    Patient age at transplantation, y      
        Less than 30 821 1.00   Poverall < .001 
        30-39 330 1.49 1.19 1.86 .001 
        40-49 226 1.52 1.17 1.96 .002 
        50 or more 144 1.89 1.36 2.63 < .001 
    KPS before transplantation      
        Less than 80% 119 1.00   Poverall = .014 
        80% or more 1339 0.65 0.48 0.87 .005 
        Missing 63 0.79 0.48 1.32 .37 
    Disease status before transplantation      
        CR1 802 1.00    
        CR2 719 1.35 1.11 1.63 .001 
    Type of donor      
        HLA-identical sibling 617 1.00   Poverall < .001 
        Unrelated well matched 428 1.11 0.86 1.44 .42 
        Unrelated partially matched 315 1.43 1.12 1.84 .005 
        Unrelated mismatched/unknown 161 2.47 1.88 3.25 < .001 
    Year of transplantation      
        2002-2007 784 1.00    
        1995-2001 737 1.39 1.12 1.72 .003 
    GVHD prophylaxis      
        Tacrolimus- or CSA-based ± MTX ± other 1340 1.00   Poverall = .012 
        TCD 126 1.45 1.09 1.90 .001 
        Other/none/missing 55 1.03 0.61 1.76 .91 
Relapse, main effect      
    Full intensity 1428 1.00    
    RIC 93 1.35 0.91 2.01 .14 
Relapse, other significant factors      
    KPS before transplantation      
        Less than 80% 119 1.00   .001 
        80% or more 1339 0.56 0.40 0.78 .001 
        Missing 63 0.83 0.48 1.43 .51 
    TBI given for conditioning regimen      
        Yes 1293 1.00    
        No 228 1.55 1.18 2.03 .002 
    Disease status before transplantation      
        CR1 802 1.00   Poverall < .001 
        CR2, CR1 duration < 12 mo 224 2.75 2.12 3.57 < .001 
        CR2, CR1 duration ≥ 12 mo 391 1.51 1.18 1.93 .001 
        CR2, CR1 duration missing 104 1.29 0.85 1.97 .23 
VariableNRRLower CLUpper CLP
TRM, main effect*      
        Full intensity 1428 1.00    
        RIC 93 0.98 0.66 1.46 .92 
TRM, other significant factors      
    Patient age at transplantation, y      
        Less than 30 821 1.00   Poverall < .001 
        30-39 330 1.49 1.19 1.86 .001 
        40-49 226 1.52 1.17 1.96 .002 
        50 or more 144 1.89 1.36 2.63 < .001 
    KPS before transplantation      
        Less than 80% 119 1.00   Poverall = .014 
        80% or more 1339 0.65 0.48 0.87 .005 
        Missing 63 0.79 0.48 1.32 .37 
    Disease status before transplantation      
        CR1 802 1.00    
        CR2 719 1.35 1.11 1.63 .001 
    Type of donor      
        HLA-identical sibling 617 1.00   Poverall < .001 
        Unrelated well matched 428 1.11 0.86 1.44 .42 
        Unrelated partially matched 315 1.43 1.12 1.84 .005 
        Unrelated mismatched/unknown 161 2.47 1.88 3.25 < .001 
    Year of transplantation      
        2002-2007 784 1.00    
        1995-2001 737 1.39 1.12 1.72 .003 
    GVHD prophylaxis      
        Tacrolimus- or CSA-based ± MTX ± other 1340 1.00   Poverall = .012 
        TCD 126 1.45 1.09 1.90 .001 
        Other/none/missing 55 1.03 0.61 1.76 .91 
Relapse, main effect      
    Full intensity 1428 1.00    
    RIC 93 1.35 0.91 2.01 .14 
Relapse, other significant factors      
    KPS before transplantation      
        Less than 80% 119 1.00   .001 
        80% or more 1339 0.56 0.40 0.78 .001 
        Missing 63 0.83 0.48 1.43 .51 
    TBI given for conditioning regimen      
        Yes 1293 1.00    
        No 228 1.55 1.18 2.03 .002 
    Disease status before transplantation      
        CR1 802 1.00   Poverall < .001 
        CR2, CR1 duration < 12 mo 224 2.75 2.12 3.57 < .001 
        CR2, CR1 duration ≥ 12 mo 391 1.51 1.18 1.93 .001 
        CR2, CR1 duration missing 104 1.29 0.85 1.97 .23 

CL indicates confidence limit.

*

Stratified variable: graft type.

Close Modal

or Create an Account

Close Modal
Close Modal